Inclusion Criteria:

- Histologically proven adenocarcinoma or squamous cell carcinoma of the Oesophagus,
O-G junction, stomach and pancreas, not amenable to surgical resection.

- Bidimensionally measurable disease, or unidimensional measurable disease accessible
by CT scanning, not within previously irradiated areas.

- Patients with progressive disease during previous chemotherapy treatment or within
three months of stopping treatment.

- At least one previous chemotherapy regimen, given at least 4 weeks prior to inclusion
in this study.

- No previous exposure to irinotecan.

- Adequate bone marrow function with platelets >100 X 109/L; WBC > 3 X 109/L;
Neutrophils > 1.5 X 109/L at the time of study entry.

- Satisfactory renal function, serum creatinine 135 mol/litre

- Satisfactory liver function:

- In the absence of liver metastases:- Bilirubin < 1.25N (N=upper limit of normal
range) Hepatic transaminases < 2.5N Prothrombin time < 1.5N

- In the presence of liver metastases:- Bilirubin < 1.5N Hepatic transaminases < 5N
Prothrombin time < 1.5N

- No uncontrolled medical condition

- No previous malignant disease except for non-melanotic skin cancer or in-situ
carcinoma of the uterine cervix.

- ECOG performance status of 0, 1 or 2.

- Predicted life expectancy of > 3 months.

- Adequate contraceptive precautions

- Informed written consent

Exclusion Criteria:

- Medical or psychiatric conditions resulting in inability of patient to give written
consent.

- ECOG Performance status >2

- Intracerebral metastases or meningeal carcinomatosis

- Unresolved bowel obstruction

- Uncontrolled angina pectoris, heart failure (New York heart classification 3 or 4).

- Pregnancy/lactation

- Previous malignancy other than adequately treated basal cell carcinoma of the skin or
cervical carcinoma in situ.